• About us
  • Privacy Policy
  • Contact us
Neo Science Hub
ADVERTISEMENT
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
    • Healthcare & Medicine
    • Pharmaceutical & Chemical
    • Automobiles
    • Blogs
      • Anil Trigunayat
      • BOOKmarked
      • Chadha’s Corner
      • Cyber Gyan
      • Raul Over
      • Taste of Tradition
        • Dr. G. V. Purnachand
      • Vantage
    • Business Hub
    • Engineering
    • Innovations
    • Life Sciences
    • Space Technology
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In
No Result
View All Result
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
    • Healthcare & Medicine
    • Pharmaceutical & Chemical
    • Automobiles
    • Blogs
      • Anil Trigunayat
      • BOOKmarked
      • Chadha’s Corner
      • Cyber Gyan
      • Raul Over
      • Taste of Tradition
        • Dr. G. V. Purnachand
      • Vantage
    • Business Hub
    • Engineering
    • Innovations
    • Life Sciences
    • Space Technology
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In
No Result
View All Result
Neo Science Hub
No Result
View All Result
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In

Unraveling the Influenza Vaccine Shake-Up

Neo Science Hub by Neo Science Hub
3 years ago
in Pharmaceutical & Chemical, Science News
3
The Lancet Infectious Diseases | Neo Science Hub

The Lancet Infectious Diseases | Neo Science Hub

The recent recommendation by the World Health Organization (WHO) to exclude the influenza B/Yamagata lineage from future influenza vaccines has sparked a significant shake-up in the field of influenza vaccination. This move was highlighted in the editorial of ‘The Lancet’ edition on ‘Infectious Diseases’ of December 2023 edition. It has far-reaching implications for vaccine formulation, distribution strategies, and future influenza control efforts. In this commentary, NSH delves into the Lancet editorial’s key points, provide critical analysis, and discuss the potential impact of this influenza vaccine shake-up.

Excluding the B/Yamagata lineage

‘The Lancet’ Infectious Diseases editorial, published in December 2023, sheds light on the unprecedented decision made by the WHO to exclude the B/Yamagata lineage from influenza vaccines for the upcoming season in the Southern Hemisphere. The editorial highlights the unique circumstances surrounding this decision, including the substantial drop in B/Yamagata cases amid the COVID-19 pandemic and the absence of isolated or sequenced B/Yamagata viruses since March 2020.

The Lancet Infectious Diseases Cover | Neosciencehub
The Lancet Infectious Diseases Cover | Neosciencehub

We’re on the Same Page

In this context, NSH is also on the same page with ‘Lancet’, and echoes the same opinion on the  exclusion of B/Yamagata from seasonal influenza vaccines carries significant implications, both in terms of vaccine formulation and distribution strategies. Historically, quadrivalent vaccines containing both B/Yamagata and B/Victoria lineages were used to mitigate the risk of mismatch between circulating influenza B viruses and vaccine strains. However, with the decline of B/Yamagata transmission, trivalent vaccines may now emerge as the preferred choice.

The adoption of trivalent vaccines could lead to a simplification of influenza vaccine campaigns, potentially resulting in cost savings and increased accessibility. However, manufacturers face a challenging decision regarding whether to focus solely on trivalent vaccines or to update quadrivalent formulations with a different influenza A lineage instead of B/Yamagata. Such an update would require modifying potency assays and potentially conducting clinical trials to ensure the effectiveness of the revised quadrivalent vaccines.

The editorial rightly points out that continued surveillance for B/Yamagata is crucial to detect any possible resurgence of this lineage. While WHO’s recommendation pertains to the Southern Hemisphere, it is anticipated that similar changes may be recommended for the Northern Hemisphere as well, which would necessitate a global reassessment of influenza vaccination strategies.

The observations also raise questions about the impact of this shake-up on the development of new influenza vaccines. Manufacturers with ongoing clinical trials of quadrivalent mRNA vaccines, such as Moderna and Pfizer, may need to reassess their formulations to exclude B/Yamagata. Additionally, Novavax’s trials with recombinant haemagglutinin proteins from four influenza strains, including B/Yamagata, may need to be revisited.

‘The Lancet’ Infectious Diseases editorial presents a thorough examination of the influenza vaccine shake-up prompted by the exclusion of the B/Yamagata lineage from future vaccines. The decision made by WHO reflects the unprecedented circumstances faced during the COVID-19 pandemic and emphasizes the dynamic nature of influenza control measures. While challenges and uncertainties lie ahead, this shake-up presents an opportunity for simplifying vaccination campaigns, reducing costs, and exploring alternative vaccine formulations to ensure broader coverage against influenza.

Share this:

  • Share on X (Opens in new window) X
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on Facebook (Opens in new window) Facebook
  • Share on WhatsApp (Opens in new window) WhatsApp
  • Share on Tumblr (Opens in new window) Tumblr
  • Share on Telegram (Opens in new window) Telegram
  • Email a link to a friend (Opens in new window) Email
Tags: B/Yamagata ExclusionfeaturedInfluenza VaccinePandemic ImpactsciencenewsVaccine StrategyWHO Decision
Neo Science Hub

Neo Science Hub

NEO SCIENCE HUB is envisaged as a Web Portal and E-Magazine to provide digital access to the cutting edge and advanced technology, hosted across the globe in all the disciplines of Science

Other Posts

Dilemma of a Country With More Hands Than Jobs

Humanoid Robots and India: The Dilemma of a Country With More Hands Than Jobs

November 22, 2026
0
If Machines Do the Work, What Is Left for Us?

If Machines Do the Work, What Is Left for Us?

November 22, 2026
0

When the Last Antibiotic Fails: ICMR Finds 91 Per Cent Carbapenem Resistance in a Common Hospital Pathogen

Akvan Turns North and Drops a Category: IMD Now Expects a Severe Cyclone Between Narsapur and Puri, While Andhra’s Own Forecasters Expect Less

Antalya’s Last Forty-Eight Hours: Two Contradictory Paragraphs on Fossil Fuels, and India’s Line on the Carbon Budget

Disarm, Don’t Kill: CCMB Scientists Find Two Compounds That Stop a Deadly Fungus Turning Invasive

Eighty Per Cent of the Cost: Andhra Pradesh Raises the Stakes in India’s Chip-Subsidy Contest

Before the First Breath: UNEP and WHO Say Hormone-Disrupting Chemicals Reach Us in the Womb

Next Post
Dexamethasone in Severe COVID-19 | Neosciencehub

Dexamethasone in Severe COVID-19

Please login to join discussion

Subscribe to Us

Latest Articles

Cross-section of a human eye with the optic nerve head highlighted

FDA Orders Eye-Risk Warnings on All GLP-1 Drugs, From Ozempic to Mounjaro

November 12, 2026
11

Delhi’s Diwali, Measured: Firecrackers Drove 71% of Fine Particles, Lead Hit 20 Times the Limit, and the Worst Readings Went Missing

Global Carbon Budget 2026: The World’s Fossil Emissions Dip, India’s Rise 4.4%, and the 1.5 °C Budget Is Nearly Spent

A New Kind of Blood Thinner: FDA Approves Asundexian to Prevent Repeat Strokes

Andhra Pradesh Opens the Door to Small Nuclear Reactors, Robots and Giga-Scale AI Data Centres — With the Details Still to Come

“Off the Charts”: WMO Tells COP31 That 2026 Is Among the Hottest Years on Record as a Record El Niño Builds

  • Advertise
  • Terms and Conditions
  • Privacy Policy
  • Refund Policy
  • Contact
For Feedback : Email Us

Copyrights © 2025 Neo Science Hub

No Result
View All Result
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
    • Healthcare & Medicine
    • Pharmaceutical & Chemical
    • Automobiles
    • Blogs
      • Anil Trigunayat
      • BOOKmarked
      • Chadha’s Corner
      • Cyber Gyan
      • Raul Over
      • Taste of Tradition
      • Vantage
    • Business Hub
    • Engineering
    • Innovations
    • Life Sciences
    • Space Technology
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In

Copyrights © 2025 Neo Science Hub

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist